Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × OTHER × Alemtuzumab × Clear all

Phase

Status

Completed 61 Terminated 26 Withdrawn 4 Unknown 4 Active not recruiting 3 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pseudomyxoma Peritonei 1

Interventions

Drug Therapy 95 Cisplatin 88 Carboplatin 77 Radiotherapy 75 Oxaliplatin 70 Bevacizumab 70 Capecitabine 61 Gemcitabine 60 pembrolizumab 57 Paclitaxel 56 Cyclophosphamide 56 tislelizumab 55 toripalimab 53 sintilimab 46 Surgical Procedures, Operative 46 Fluorouracil 46 Specimen Handling 45 Magnetic Resonance Spectroscopy 40 130-nm albumin-bound paclitaxel 40 Immune Checkpoint Inhibitors 36 anlotinib 35 Radiosurgery 35 lenvatinib 31 Biopsy 31 Standard of Care 30 Leucovorin 30 Blood Specimen Collection 30 Docetaxel 29 apatinib 28 fludarabine 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06084780 2026-01-23

TRANSCAPE

Case Comprehensive Cancer Center

Phase 2 Not yet recruiting

Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon ⚡